Expanding the Patient Pool for Rilonacept

Expanding the Patient Pool for Rilonacept

Recurrent pericarditis complicates 15%-30% of acute pericarditis cases despite initial anti-inflammatory treatment. The RHAPSODY trial (Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis) showed rilonacept, an interleukin-1 cytokine trap, to b...

Full description

Saved in:
Bibliographic Details
Main Authors: Emma St. John, MD, Jessica R. Carey, PharmD, Tanya Wilcox, MD, John Ryan, MD, Satvik Ramakrishna, MD, Anees Daud, MD, Denise Diaz-Robles, PA-C, Adam Smith, PharmD, Kristin Cowan, CPh-T, Libo Wang, MD
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:JACC: Case Reports
Subjects:
interleukin-1
recurrent pericarditis
rilonacept
Online Access:http://www.sciencedirect.com/science/article/pii/S2666084925005777
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

http://www.sciencedirect.com/science/article/pii/S2666084925005777

Similar Items